Over-expression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells

Lara Pickel1, Takaya Matsuzuka1, Chiyo Doi1

  • 1Department of Anatomy & Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA.

Cancer Biology & Therapy
|December 23, 2009
PubMed

Insights

Over-expressing the angiotensin II type 2 receptor (AT2) in lung adenocarcinoma cells triggers apoptosis, inhibiting cancer cell growth. Biodegradable nanoparticles show promise for targeted AT2 gene therapy in lung cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biotechnology

Background:

  • The angiotensin II type 2 receptor (AT2) is known to induce apoptosis in cardiovascular tissues.
  • Investigating AT2 receptor's role in cancer offers potential therapeutic strategies.

Purpose of the Study:

  • To explore the anti-cancer effects of AT2 receptor over-expression in lung adenocarcinoma cells.
  • To evaluate adenoviral, FuGENE, and nanoparticle vectors for AT2 gene delivery.

Main Methods:

  • Gene transfection using adenoviral (Ad), FuGENE, and poly (lactide-co-glycolic acid) (PLGA) nanoparticle vectors.
  • Assessing cell viability via direct cell count and apoptosis via flow cytometry (annexin V).
  • Confirming apoptosis pathway activation using Western Blot analysis for caspase-3.

Main Results:

  • All tested vectors efficiently transfected AT2 cDNA into lung cancer cells with minimal impact on normal cells.
  • Ad-AT2 significantly reduced lung cancer cell growth (A549, H358) compared to Ad-LacZ.
  • AT2 over-expression activated apoptosis, confirmed by annexin V staining and caspase-3 activation.
  • PLGA nanoparticles effectively delivered AT2 plasmid DNA, increasing AT2 expression and cell death in A549 cells.

Conclusions:

  • AT2 receptor over-expression effectively inhibits lung adenocarcinoma cell growth by inducing intrinsic apoptosis.
  • PLGA nanoparticles represent a viable and efficient gene delivery vector for targeted lung adenocarcinoma therapy.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...